Replies to post #225970 on Biotech Values

[DewDiligence]

NBRV—(-43% Friday)—reports $93K Xenleta sales in 4Q19:

https://finance.yahoo.com/news/nabriva-therapeutics-reports-fourth-quarter-200110344.html

The $93K sales figure for 4Q19 not a typo! Cumulative Xenleta sales since the Aug 2019 FDA approval are only $1.5M.

h/t ‘rkrw’ for catching typo in earlier version of this message.